Navigation Links
Wayne State vision restoration technology receives Notice of Allowance for US patent app

DETROIT Technology to restore vision through the use of a component of green algae developed by Dr. Zhou-Han Pan, professor and scientific director of the Ligon Research Center of Vision at the Kresge Eye Institute at Wayne State University, and licensed to RetroSense Therapeutics, a biotechnology company dedicated to developing gene therapy approaches to vision restoration, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. patent application (No. 12/299,574). The notice broadly covers methods of restoring visual responses with a variety of optogenetic compounds.

The application includes claims covering methods of restoring visual responses by delivery to retinal neurons any of a number of channelrhodopsin variants, as well as halorhodopsin. The two molecules have been studied extensively and published on as means of vision restoration in retinal degenerative conditions such as retinitis pigmentosa and dry age-related macular degeneration.

The approved patent application is part of the "Pan" patent family, which stems from the novel research of Pan and others at Wayne State University and Salus University, designed to restore vision in retinal degenerative conditions. Several Pan patent applications are part of RetroSense's intellectual property estate, which focuses on optogenetic gene therapies and complementary devices for vision restoration.

"We are pleased that the U.S. Patent Office has allowed this patent application, which will substantively expand the coverage of RetroSense's intellectual property estate," said Sean Ainsworth, chief executive officer of RetroSense. "Our IP position provides broad protection. RetroSense continues to develop novel intellectual property in the area of optogenetics. Accordingly, we plan to continue to extend our basic patent protections on our technologies. We have also maintained an ongoing strategy to consolidate key intellectual property required to develop and commercialize optogenetics to restore visual responses."

The newly allowed U.S. patent application covers methods of increasing visually evoked potentials by delivering to retinal neurons one or more of the following molecules:

  • Channelrhodopsin-2 (and a multitude of variants thereof)
  • Halorhodopsin

Claims also explicitly cover targeting these molecules with cell-type specific promoters, including mGluR6 (Grm6).

Following a Notice of Allowance, the process resulting in final issuance of a patent involves several administrative steps that are typically completed within a year.


Contact: Julie O'Connor
Wayne State University - Office of the Vice President for Research

Related biology news :

1. Wayne State study shows airborne dust in urban areas impacts lead levels in children
2. Wayne State University researchers techniques enable more, faster testing of biological liquids
3. Cancer risk for African-American women with benign breast disease factors Wayne State finds
4. High-strength material advancements at Wayne State University may lead to new, life-saving steel
5. New book on physics principles by Wayne State professor explains life as we know it
6. Wayne State receives $2.8 million grant from US Administration for Children and Families
7. Wayne State researchers working to improve genetic analysis, disorder detection
8. Wayne State University researchers program targets safer river fishing, anglers health
9. Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office
10. Iowa State computer, electrical engineers working to help biologists cope with big data
11. Thomas Jefferson University researchers discover new pathways that drive metastatic prostate cancer
Post Your Comments:
(Date:11/17/2015)... Paris from 17 th ... Paris from 17 th until 19 th ... leader, has invented the first combined scanner in the world ... scanning surface. Until now two different scanners were required: one ... both on the same surface. This innovation is an ...
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
(Date:11/11/2015)... MINNETONKA, Minn. , Nov. 11, 2015   MedNet ... the entire spectrum of clinical research, is pleased to announce ... Partnerships in Clinical Trials (PCT) event, to be held ... will be able to view live demonstrations of ... platform, and learn how iMedNet has been able ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... company uBiome, were featured on AngelList early in their initial angel funding process. ... AngelList syndicate for individuals looking to make early stage investments in the microbiome ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
(Date:11/24/2015)... , November 24, 2015 ... market research report "Oligonucleotide Synthesis Market by Product & ... Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & ... by MarketsandMarkets, the market is expected to reach USD ... 2015, at a CAGR of 10.1% during the forecast ...
Breaking Biology Technology: